More on VRXA
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.48 |
|
|||
| Open | $2.49 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $2.50 | ||||
| Day Low | $2.13 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 504,833 | ||||
- Form 6-K Veraxa Biotech AG For: Jul 10
- VERAXA Biotech names Carl von Halem as interim CFO
- VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
- Form 6-K Veraxa Biotech AG For: Jul 06
- VERAXA Biotech targets first BiTAC candidate IND-ready by 2028
- VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
- Veraxa Biotech starts cell line development with ATUM for cancer therapy
- VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
- VERAXA Biotech expands lab space at Heidelberg R&D site
- VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
Entities mentioned with VRXA
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Cantor Fitzgerald | View Related Stories »
- SPAC | View Related Stories »
- IPO | View Related Stories »
- Show More...
